Trending Articles

Star Therapeutics launches Vega, growing its galaxy of drug startups

Bio Pharma Dive

The second startup to emerge from Star’s “hub-and-spoke” model aims to develop a Hemlibra-like antibody drug for the blood clotting disorder von Willebrand disease

Third Circuit Court of Appeals Upends “Intended Loss”

The FDA Law Blog

By Douglas B. Farquhar & John W.M.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout

Bio Pharma Dive

After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal

Drugs 263

Get Set up for Success in the Account Incubator Program

Intouch Solutions

Finding an agency job after graduating college can feel overwhelming, but it doesn’t have to. Jumpstart your career at EVERSANA INTOUCH and be set up for success as part of our Account Incubator program where you can dip your toes into an Account Services role!

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

Elon Musk’s Neuralink brain interface chip set for human trials

Pharma Phorum

Clinical trials of a wireless brain chip developed by Elon Muck’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have one implanted for a future demo event.

The European Commission and WHO extend their strategic cooperation to deliver better health for all

The Pharma Data

The European Commission and WHO extend their strategic cooperation to deliver better health for all.

More Trending

GSK, Sanofi, Pfizer and Boehringer Ingelheim free from federal Zantac litigation with new ruling

Fierce Pharma

GSK, Sanofi, Pfizer and Boehringer Ingelheim free from federal Zantac litigation with new ruling. zbecker. Wed, 12/07/2022 - 10:05

82

GSK, Sanofi, and Takeda align with research communities to advance Singapore's biologics manufacturing capabilities

BioPharma Reporter

Global pharma giants, GSK, Sanofi, and Takeda, are set to collaborate with Singapore researchers to boost innovation in local biologics and vaccines manufacturing. Markets & Regulations

How a new investment is powering a revolution in clinical trial operations

Pharma Phorum

Clinical trials are the engine for pharmaceutical innovation, but their means of capturing and communicating data are stuck in the past.

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

The Pharma Data

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy. Novartis.

HR 59

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker

Fierce Pharma

With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker. fkansteiner. Fri, 12/02/2022 - 09:51

Drugs 94

Protracted Job Searches Exact Weighty Mental Health Toll

BioSpace

Whether a job search is voluntary or not, the psychological toll of months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll

87

Pfizer, BioNTech submit to FDA for Covid vaccine in under 5s

Pharma Phorum

Sanofi and Queensland collaborate to build $190m research facility

Pharmaceutical Technology

Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub.

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Novartis prostate cancer drug succeeds in study key to company’s sales hopes

Bio Pharma Dive

The positive results could help Novartis secure approval for earlier use of the radiopharmaceutical drug Pluvicto, potentially broadening the number of eligible patients by several times the current market

Sales 246

With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2

Fierce Pharma

With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. kdunleavy. Thu, 12/01/2022 - 10:14

91

Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

The Pharma Data

Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer.

Drugs 55

Addressing leadership barriers for women in tech and pharma

Pharma Phorum

Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry. However, both industries share a common problem: failure to provide women with C-suite opportunities.

CVS, Walgreens, and Walmart Keep Position in 2023 Part D Preferred Networks—While Kroger Bails Over its Express Scripts Blowup

Drug Channels

In Preferred Pharmacy Networks in 2023’s Medicare Part D Plans: Cigna, CVS Health, Humana, UnitedHealthcare, WellCare, and More , I highlighted how those networks have taken over the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans.

Drugs 79

Rigel wins US approval of rival drug to Servier leukemia treatment

Bio Pharma Dive

The approval gives Rigel, a biotech that’s been around since the mid-1990s, its second marketed medicine and a competitor to Servier’s Tibsovo

SABCS: Lilly aims Verzenio at broader post-surgery breast cancer nod as Novartis' rival draws near. Will FDA bite?

Fierce Pharma

SABCS: Lilly aims Verzenio at broader post-surgery breast cancer nod as Novartis' rival draws near. Will FDA bite? Mon, 12/05/2022 - 15:10

82

AeroSafe Global Awarded Environmental Management Certification

Pharmaceutical Commerce

Confirms cold chain company’s sustainability commitment.

52

Valneva eyes first place in chikungunya vaccine race

Pharma Phorum

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today.

Pharma Worries as Twitter Upheaval Continues

Eversana Intouch

Justin Chase, SVP, Media, EVERSANA INTOUCH, was recently interviewed by Endpoints News for an article on how pharmaceutical companies are handling both paid and organic interaction on Twitter in the era of Elon Musk ownership.

52

FDA lifts pause on Beam plans to test base editing cancer therapy

Bio Pharma Dive

The FDA’s decision is a step forward for a type of drugmaking known as “multiplex editing,” which involves editing several genes simultaneously

Gene 252

AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit

Fierce Pharma

AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit. zbecker. Mon, 12/05/2022 - 10:31

82

GSK, Sanofi, and Takeda Partner with Singapore on Biologics Innovation

Pharmaceutical Commerce

Big Pharma to collaborate with researchers from A*STAR, along with Singapore universities.

52

New Nkarta data backs up natural killer approach to cancer treatment

Pharma Phorum

Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology – but one that is garnering increased interest as clinical trials start to generate data.

What FDA’s Newest Gene Therapy Approval Tells Us About Durability: How Long is Long Enough?

The FDA Law Blog

By Mark A. Tobolowsky & James E.

52

Pfizer, Roivant set up new company around inflammation drug

Bio Pharma Dive

The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing

PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex

Fierce Pharma

PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex. ntaylor. Thu, 12/01/2022 - 11:05

90

PureTech Reveals New CBD Pill to Rival Jazz’s Epidiolex

XTalks

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups.

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database.

MEI Abandons PI3K Inhibitor, 30% of Staff in Strategic Shift

BioSpace

MEI Pharma, Inc. will have a strategic realignment that would see at least 30% of its workforce laid off and a pivot towards two of its earlier clinical-stage assets

80